Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does “positive” even mean, really?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss some confusing new clinical data in Alzheimer’s disease that has led to controversy around a Biogen-developed treatment for Alzheimer’s disease. STAT’s Lev Facher joins us to discuss how the issue of drug pricing is shaping races across the U.S. ahead of the midterm elections. And then we explore how crowdfunded science for ultra-rare diseases has led to some inspiring stories and shined a light on a gray area in biotech research. Finally, we run through a packed week of biotech earnings, a hotly contested new depression treatment, and mounting competition in the monopolistic world of genome sequencing.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy